MedTrace Logo

Recombinant Human Interleukin-11 Combination Low-dose Rituximab in Immune Thrombocytopenia

NCT01317966 · Status: WITHDRAWN · Type: OBSERVATIONAL

Last updated 2016-04-20

No results posted yet for this study

Summary

The purpose of this study is to determine whether Recombinant Human Interleukin-11 (rhIL-11) Combination Low-dose Rituximab prednisone are effective and safe in the management of Steroid-Resistant/Relapsed Immune Thrombocytopenia (ITP).

Conditions

  • Purpura, Thrombocytopenic, Idiopathic

Interventions

DRUG

rhIL-11

Recombinant Human Interleukin-11 (rhIL-11) Combinating Low-dose Rituximab

Sponsors & Collaborators

  • Peking Union Medical College Hospital

    collaborator OTHER

  • Chinese Academy of Medical Sciences

    collaborator OTHER

  • First Affiliated Hospital, Sun Yat-Sen University

    collaborator OTHER

  • West China Hospital

    collaborator OTHER

  • Shandong Provincial Hospital

    collaborator OTHER_GOV

  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

    collaborator OTHER

  • Zhejiang University

    collaborator OTHER

  • Ming Hou

    lead OTHER

Principal Investigators

  • Ming Hou, Dr. · Shandong University

Eligibility

Min Age
16 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-03-31
Primary Completion
2011-12-31
Completion
2012-03-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01317966 on ClinicalTrials.gov